Evaluation of renal quantitative T2* changes on MRI following administration of ferumoxytol as a T2* contrast agent

PURPOSE: To evaluate the time-dependent changes in regional quantitative T2* maps of the kidney following intravenous administration of ferumoxytol. MATERIALS AND METHODS: Twenty-four individuals with normal kidney function underwent T2*-weighted MRI of the kidney before, immediately after, and 48 h...

Descripción completa

Detalles Bibliográficos
Autores principales: Hedgire, Sandeep S, McDermott, Shaunagh, Wojtkiewicz, Gregory R, Abtahi, Seyed Mahdi, Harisinghani, Mukesh, Gaglia, Jason L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4010631/
https://www.ncbi.nlm.nih.gov/pubmed/24812510
http://dx.doi.org/10.2147/IJN.S61460
_version_ 1782479885811318784
author Hedgire, Sandeep S
McDermott, Shaunagh
Wojtkiewicz, Gregory R
Abtahi, Seyed Mahdi
Harisinghani, Mukesh
Gaglia, Jason L
author_facet Hedgire, Sandeep S
McDermott, Shaunagh
Wojtkiewicz, Gregory R
Abtahi, Seyed Mahdi
Harisinghani, Mukesh
Gaglia, Jason L
author_sort Hedgire, Sandeep S
collection PubMed
description PURPOSE: To evaluate the time-dependent changes in regional quantitative T2* maps of the kidney following intravenous administration of ferumoxytol. MATERIALS AND METHODS: Twenty-four individuals with normal kidney function underwent T2*-weighted MRI of the kidney before, immediately after, and 48 hours after intravenous administration of ferumoxytol at a dose of 4 mg/kg (group A, n=12) or 6 mg/kg (group B, n=12). T2* values were statistically analyzed using two-tailed paired t-tests. RESULTS: In group A, the percentage changes from baseline to immediate post and baseline to 48 hours were 85.3% and 64.2% for the cortex and 90.8% and 64.6% for the medulla, respectively. In group B, the percentage changes from baseline to immediate post and baseline to 48 hours were 85.2% and 73.4% for the cortex and 94.5% and 74% for the medulla, respectively. This difference was significant for both groups (P<0.0001). CONCLUSION: There is significant and differential uptake of ferumoxytol in the cortex and medulla of physiologically normal kidneys. This differential uptake may offer the ability to interrogate renal cortex and medulla with possible clinical applications in medical renal disease and transplant organ assessment. We propose an organ of interest based dose titration of ferumoxytol to better differentiate circulating from intracellular ferumoxytol particles.
format Online
Article
Text
id pubmed-4010631
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-40106312014-05-08 Evaluation of renal quantitative T2* changes on MRI following administration of ferumoxytol as a T2* contrast agent Hedgire, Sandeep S McDermott, Shaunagh Wojtkiewicz, Gregory R Abtahi, Seyed Mahdi Harisinghani, Mukesh Gaglia, Jason L Int J Nanomedicine Original Research PURPOSE: To evaluate the time-dependent changes in regional quantitative T2* maps of the kidney following intravenous administration of ferumoxytol. MATERIALS AND METHODS: Twenty-four individuals with normal kidney function underwent T2*-weighted MRI of the kidney before, immediately after, and 48 hours after intravenous administration of ferumoxytol at a dose of 4 mg/kg (group A, n=12) or 6 mg/kg (group B, n=12). T2* values were statistically analyzed using two-tailed paired t-tests. RESULTS: In group A, the percentage changes from baseline to immediate post and baseline to 48 hours were 85.3% and 64.2% for the cortex and 90.8% and 64.6% for the medulla, respectively. In group B, the percentage changes from baseline to immediate post and baseline to 48 hours were 85.2% and 73.4% for the cortex and 94.5% and 74% for the medulla, respectively. This difference was significant for both groups (P<0.0001). CONCLUSION: There is significant and differential uptake of ferumoxytol in the cortex and medulla of physiologically normal kidneys. This differential uptake may offer the ability to interrogate renal cortex and medulla with possible clinical applications in medical renal disease and transplant organ assessment. We propose an organ of interest based dose titration of ferumoxytol to better differentiate circulating from intracellular ferumoxytol particles. Dove Medical Press 2014-04-28 /pmc/articles/PMC4010631/ /pubmed/24812510 http://dx.doi.org/10.2147/IJN.S61460 Text en © 2014 Hedgire et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Hedgire, Sandeep S
McDermott, Shaunagh
Wojtkiewicz, Gregory R
Abtahi, Seyed Mahdi
Harisinghani, Mukesh
Gaglia, Jason L
Evaluation of renal quantitative T2* changes on MRI following administration of ferumoxytol as a T2* contrast agent
title Evaluation of renal quantitative T2* changes on MRI following administration of ferumoxytol as a T2* contrast agent
title_full Evaluation of renal quantitative T2* changes on MRI following administration of ferumoxytol as a T2* contrast agent
title_fullStr Evaluation of renal quantitative T2* changes on MRI following administration of ferumoxytol as a T2* contrast agent
title_full_unstemmed Evaluation of renal quantitative T2* changes on MRI following administration of ferumoxytol as a T2* contrast agent
title_short Evaluation of renal quantitative T2* changes on MRI following administration of ferumoxytol as a T2* contrast agent
title_sort evaluation of renal quantitative t2* changes on mri following administration of ferumoxytol as a t2* contrast agent
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4010631/
https://www.ncbi.nlm.nih.gov/pubmed/24812510
http://dx.doi.org/10.2147/IJN.S61460
work_keys_str_mv AT hedgiresandeeps evaluationofrenalquantitativet2changesonmrifollowingadministrationofferumoxytolasat2contrastagent
AT mcdermottshaunagh evaluationofrenalquantitativet2changesonmrifollowingadministrationofferumoxytolasat2contrastagent
AT wojtkiewiczgregoryr evaluationofrenalquantitativet2changesonmrifollowingadministrationofferumoxytolasat2contrastagent
AT abtahiseyedmahdi evaluationofrenalquantitativet2changesonmrifollowingadministrationofferumoxytolasat2contrastagent
AT harisinghanimukesh evaluationofrenalquantitativet2changesonmrifollowingadministrationofferumoxytolasat2contrastagent
AT gagliajasonl evaluationofrenalquantitativet2changesonmrifollowingadministrationofferumoxytolasat2contrastagent